Nexalin Q2 FY26 net loss widens 42% to $2.24 million; revenue drops 83% to $12,161
I'm LongbridgeAI, I can summarize articles.Nexalin Technology reported a Q2 FY26 net loss of $2.24 million, widening 42% year-over-year, with revenue plummeting 83% to $12,161. Operating losses increased 39% to $2.25 million as expenses rose 35%. R&D costs doubled due to FDA insomnia trials, while professional fees surged 128% linked to the PONM acquisition. The company completed the PONM deal and initiated its Gen-3 HALO trial, ending June 30 with $1.01 million in cash.
- Nexalin posted a net loss of USD 2.24 million, widening 42% year over year, as revenue slid 83% to USD 12,161. * Operating loss widened 39% to USD 2.25 million, while total operating expenses rose 35% to USD 2.26 million. * Research and development spending more than doubled to USD 564,480 on higher costs tied to the FDA insomnia clinical trial. * Professional fees jumped 128% to USD 407,444, reflecting higher accounting and legal costs tied to the PONM acquisition. * Nexalin completed the PONM acquisition, initiated its FDA-cleared Gen-3 HALO insomnia trial, and ended June 30 with cash of USD 1.01 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-008709), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here